Pasithea Therapeutics Stock (NASDAQ: KTTA) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 0 / 3.891K |
Day Range | - - - |
52 Wk Range | 5.254 - 17.400 |
Market Cap | $8.996M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 65 |
Short Interest | 1.11% |
Days to Cover | 8.45 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Pasithea Therapeutics (NASDAQ: KTTA) through any online brokerage.
Other companies in Pasithea Therapeutics’s space includes: Eterna Therapeutics (NASDAQ:ERNA), Virios Therapeutics (NASDAQ:VIRI), Can Fite Biofarma (AMEX:CANF), BioRestorative Therapies (NASDAQ:BRTX) and NuCana (NASDAQ:NCNA).
The latest price target for Pasithea Therapeutics (NASDAQ: KTTA) was reported by EF Hutton on Monday, July 10, 2023. The analyst firm set a price target for 2.00 expecting KTTA to fall to within 12 months (a possible -76.83% downside). 2 analyst firms have reported ratings in the last year.
The stock price for Pasithea Therapeutics (NASDAQ: KTTA) is $8.6301 last updated April 8, 2024 at 5:46 PM EDT.
There are no upcoming dividends for Pasithea Therapeutics.
Pasithea Therapeutics’s Q1 earnings are confirmed for Friday, May 10, 2024.
There is no upcoming split for Pasithea Therapeutics.
Pasithea Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.